Pharmacokinetic analysis of transcellular transport of levofloxacin across LLC-PK1 and Caco-2 cell monolayers.
To characterize the membrane transport responsible for the renal excretion and intestinal absorption of levofloxacin, we performed pharmacokinetic analysis of transcellular transport across LLC-PK(1) and Caco-2 cell monolayers. Transcellular transport of levofloxacin in LLC-PK(1) cells was greater in the basolateral-to-apical direction than in the opposite direction. Pharmacokinetic analysis indicated that basolateral uptake was the direction-determining step for the transcellular transport of levofloxacin in LLC-PK(1) cells. The apical efflux clearance of levofloxacin in LLC-PK(1) cells was increased at the medium pH 6 as compared with at pH 8, suggesting that membrane transport characteristics of levofloxacin are apparently similar to those of a prototypical organic cation, tetraethylammonium. On the other hand, transcellular transport of levofloxacin in Caco-2 cells was only slightly greater in the basolateral-to-apical direction than in the opposite direction. The apical efflux clearance of levofloxacin in Caco-2 cells was greater than basolateral efflux clearance, and apical influx clearance was greater than any other membrane transport clearance. In addition, the apical uptake of levofloxacin as well as quinidine in Caco-2 cells was inhibited significantly by nicotine and imipramine. The findings indicated that some transporters are responsible not only for the efflux but also for the influx of levofloxacin at the apical membrane of Caco-2 cells.
Takaai
Mari
M
Graduate School of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Japan.
Suzuki
Hisaki
H
Ishida
Kazuya
K
Tahara
Katsutoshi
K
Hashimoto
Yukiya
Y
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001693:Biological Transport, Active / Q000187:drug effects; D018938:Caco-2 Cells; D006801:Humans; D006863:Hydrogen-Ion Concentration; D018374:LLC-PK1 Cells; D064704:Levofloxacin; D008657:Metabolic Clearance Rate; D008962:Models, Theoretical; D015242:Ofloxacin / Q000493:pharmacokinetics*; D013552:Swine
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin